Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : US extends expiration dates on J&J COVID vaccine to 6 months

07/28/2021 | 07:44pm EDT

WASHINGTON (AP) — Federal health regulators on Wednesday again extended the expiration dates on Johnson & Johnson's COVID-19 vaccine, providing health workers with six more weeks to use millions of doses of the shot.

The Food and Drug Administration said in a letter to J&J that the shots remain safe and effective for at least six months when properly stored and refrigerated. It's the second time the FDA has extended the shelf life on the vaccines since June, when the agency said they could be used for up to 4 1/2 months. When first authorized in February, the FDA said the vaccines could be stored for three months at normal refrigeration levels.

Health authorities in many states had recently warned that they could be forced to throw out thousands of doses of the one-shot vaccine without an extension.

The change gives health providers more time to use remaining shots sitting at pharmacies, hospitals and clinics. After plateauing earlier this summer, vaccination rates have begun climbing again as the contagious delta variant surges across many parts of the country.

Vaccine expiration dates are based on information from drugmakers on how long the shots stay at the right strength. J&J previously stated that it continues to conduct stability testing with the aim of further extending the shelf life of the shots.

The FDA has been reviewing expiration dates on all three U.S.-authorized vaccines as companies have continued to test batches in the months since the shots first rolled out. Vaccines from Pfizer and Moderna, authorized in December, have a six-month shelf life.

J&J’s vaccine was highly anticipated because of its one-and-done formulation and easy-to-ship refrigeration.

But rival drugmakers Pfizer and Moderna, which started shipping shots months earlier, have already supplied more than enough doses to vaccinate all eligible Americans. More than 150 million Americans have been fully vaccinated with the companies’ two-dose shots. By comparison, just 13 million Americans have been vaccinated with the J&J shot.

Use of J&J’s vaccine has been hurt by several rare potential side effects. Earlier this month, U.S. health regulators added a new warning to the vaccine about links to a potentially dangerous neurological reaction called Guillain-Barré syndrome.

That followed a pause in the use of the shot in April after it was linked to a rare blood clot disorder. In both cases, government health advisers said the overall benefits of the shot still greatly outweigh the risks.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Copyright 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source Associated Press News

All news about JOHNSON & JOHNSON
12:53pJOHNSON & JOHNSON : Unit Collaborates With Persephone Biosciences On Stool Analysis
MT
10:06aShangula Rages Against West's Vaccine Nationalism
AQ
09:55aJOHNSON & JOHNSON : Data Shows COVID-19 Booster Shots 94% Effective Against Moderate to Se..
MT
09:40aToday on Wall Street: Markets at a pivot point
08:27aJOHNSON & JOHNSON : Says New Data Show Booster Shot Increases COVID-19 Protection
MT
08:01aJ&J : Booster dose of its COVID shot prompts strong response
AQ
07:38aJOHNSON & JOHNSON : Says New Data Shows a Booster of its One-Shot Vaccine Increases COVID-..
MT
06:31aJOHNSON & JOHNSON : Announces Real-World Evidence and Phase 3 Data Confirming Strong and L..
PR
05:12aJOHNSON & JOHNSON : COVID-19 Vaccine to Reportedly Arrive in India Next Month
MT
09/20JOHNSON & JOHNSON : The Janssen Pharmaceutical - RYBREVANT (amivantamab-vmjw) Provides Hig..
AQ
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 407 M - -
Net income 2021 22 809 M - -
Net Debt 2021 1 880 M - -
P/E ratio 2021 19,1x
Yield 2021 2,53%
Capitalization 433 B 433 B -
EV / Sales 2021 4,61x
EV / Sales 2022 4,41x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 164,53 $
Average target price 185,83 $
Spread / Average Target 12,9%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.09%431 227
ROCHE HOLDING AG10.52%321 941
PFIZER, INC.19.23%247 816
NOVO NORDISK A/S48.69%229 255
ELI LILLY AND COMPANY37.20%210 000
ABBVIE INC.-0.70%188 027